Psychiatry

AMC Bipolar Disorder & Lithium MCQs

This page explains how the AMC MCQ exam tests bipolar disorder and lithium: recognising mania and hypomania, choosing a mood stabiliser, and spotting lithium toxicity before it becomes dangerous. It ends with three practice questions written to the AMC single-best-answer style.

Most tested
Lithium toxicity precipitants and management; mania versus hypomania
Guideline to know
RANZCP clinical practice guidelines for mood disorders; Therapeutic Guidelines: Psychotropic
Classic trap
Giving an antidepressant alone to a patient with bipolar depression
Study time
3–4 hours

What the AMC tests in bipolar disorder

Bipolar disorder questions sit in two groups. The first is diagnosis: recognising a manic or hypomanic episode from a short history, separating bipolar I from bipolar II, and not mistaking mania for a drug effect or an organic illness. The second, and the larger, is drug safety, with lithium at the centre.

Lithium is a favourite because it has a narrow therapeutic range, many common interactions and clear clinical signs of toxicity. A stem might describe a patient on lithium who starts a new blood pressure tablet, takes ibuprofen for back pain, or has gastroenteritis, and then becomes tremulous and confused. The answer is to stop lithium, check a level and support renal function, not to add another drug.

Other mood stabiliser questions test valproate in women who could become pregnant, lamotrigine and its rash risk, and the role of antipsychotics in acute mania. You should also know how bipolar disorder affects pregnancy and the postpartum period, where the risk of relapse and postpartum psychosis is high.

  • Mania versus hypomania versus mixed features
  • Bipolar I versus bipolar II versus cyclothymia
  • Acute mania management, including stopping antidepressants
  • Lithium monitoring, side effects, interactions and toxicity
  • Valproate, lamotrigine and carbamazepine safety points

Diagnosis: mania, hypomania and the bipolar types

A manic episode is a distinct period of elevated, expansive or irritable mood with increased energy, lasting at least one week (or any duration if hospital admission is needed), with marked impairment or psychotic features. Typical features are reduced need for sleep, pressured speech, flight of ideas, grandiosity, distractibility and risky behaviour such as spending or sexual disinhibition.

Hypomania has similar features for at least four days, but without marked impairment, psychosis or the need for admission. Other people notice the change, but the person keeps functioning. A stem that says 'his colleagues noticed he was unusually productive and talkative for a week' is describing hypomania.

Bipolar I disorder requires at least one manic episode. Bipolar II requires at least one hypomanic episode and at least one major depressive episode, without ever having had mania. Cyclothymia involves at least two years of fluctuating hypomanic and depressive symptoms that never meet full criteria.

Before you diagnose primary bipolar disorder, exclude causes. Stimulants such as methamphetamine, corticosteroids, hyperthyroidism, and neurological disease such as frontal lesions can all cause manic symptoms. A first manic episode in an older person, or with confusion, needs a medical work-up.

  • Mania: one week or more, marked impairment, admission or psychosis
  • Hypomania: four days or more, no marked impairment, no psychosis
  • Bipolar I: at least one manic episode
  • Bipolar II: hypomania plus major depression, never mania
  • Antidepressant-triggered mania that persists beyond the drug effect still counts toward bipolar disorder

Managing acute mania and bipolar depression

Acute mania is often managed in hospital because judgement is impaired and risk is high, including financial, sexual and physical risk. Many patients lack insight and capacity, so involuntary treatment under the state Mental Health Act may be needed.

First steps are to stop any antidepressant, check for substance use and medical causes, and start an antimanic drug. Options include a second-generation antipsychotic, lithium or valproate, alone or in combination depending on severity. A benzodiazepine can be used short-term for agitation and sleep.

Bipolar depression is harder to treat than mania. Antidepressant monotherapy should be avoided because it can trigger a switch to mania or rapid cycling. Options with evidence include quetiapine, lurasidone, lamotrigine (more for maintenance and prevention of depressive relapse) and lithium. If an antidepressant is used, it should be combined with a mood stabiliser and closely monitored.

Long-term, lithium remains a strong maintenance option and is the mood stabiliser with the best evidence for reducing suicide. Psychoeducation, a relapse signature plan, regular sleep, and avoiding alcohol and drugs are part of every maintenance plan.

  • Acute mania: stop antidepressants, start antipsychotic, lithium or valproate
  • Short-term benzodiazepine for agitation and sleep
  • Bipolar depression: avoid antidepressant monotherapy
  • Lithium has the strongest evidence for suicide reduction
  • Teach early warning signs and keep sleep regular

Lithium: monitoring, side effects and toxicity

Before starting lithium, check renal function, electrolytes, thyroid function, calcium, weight, and an ECG if there is cardiac disease or the patient is older. Ask about pregnancy and contraception. Explain the need for regular blood tests and how to avoid dehydration.

Serum lithium levels are taken about 12 hours after the last dose. Levels are checked several days after starting or changing the dose, then regularly once stable, along with renal function, thyroid function and calcium at least every six to twelve months. Use the laboratory and Therapeutic Guidelines target ranges rather than memorising one number.

Common side effects include fine tremor, polyuria and thirst, weight gain, and gastrointestinal upset. Long-term effects include hypothyroidism, hyperparathyroidism with hypercalcaemia, nephrogenic diabetes insipidus and chronic kidney disease. These are why monitoring continues for as long as the patient takes lithium.

Toxicity is caused by anything that reduces lithium excretion or raises its concentration: dehydration from vomiting, diarrhoea or heat; reduced salt intake; renal impairment; and drugs such as NSAIDs, ACE inhibitors, angiotensin receptor blockers and thiazide diuretics. Signs progress from coarse tremor, nausea, vomiting and diarrhoea to ataxia, slurred speech, confusion, myoclonus, seizures and reduced consciousness.

Management of suspected toxicity is to stop lithium, check a level urgently with renal function and electrolytes, give intravenous fluids to restore volume, and seek toxicology advice. Activated charcoal does not bind lithium. Haemodialysis is used in severe toxicity, especially with neurological signs or poor renal function. Clinical features matter more than the level alone, particularly in chronic toxicity.

  • Lithium level about 12 hours post-dose
  • Monitor renal function, thyroid function and calcium long-term
  • NSAIDs, ACE inhibitors, ARBs, thiazides and dehydration raise levels
  • Coarse tremor, ataxia and confusion suggest toxicity
  • Charcoal does not help; dialysis for severe cases

Valproate, lamotrigine and carbamazepine

Valproate is effective in acute mania and maintenance but is highly teratogenic, with risks of neural tube defects and neurodevelopmental harm. In Australia, the TGA and specialist guidance say valproate should not be used in women and girls who could become pregnant unless other treatments are unsuitable and effective contraception and specialist oversight are in place. In an exam stem about a young woman with bipolar disorder, valproate is rarely the best first answer.

Lamotrigine is useful for preventing bipolar depression. Its key risk is serious rash, including Stevens-Johnson syndrome, which is more likely with fast dose increases. Valproate roughly doubles lamotrigine levels, so the lamotrigine dose must be lower when the two are combined.

Carbamazepine is a strong enzyme inducer. It lowers levels of many drugs, including the combined oral contraceptive pill, and can cause hyponatraemia, agranulocytosis and serious rash. It is used less often now but still appears in interaction questions.

  • Valproate: avoid in women of childbearing potential unless no alternative
  • Lamotrigine: slow titration to reduce rash risk
  • Valproate raises lamotrigine levels
  • Carbamazepine induces enzymes and reduces contraceptive effectiveness

Australian practice points

Australian guidance on bipolar disorder comes mainly from the RANZCP mood disorders guideline and Therapeutic Guidelines. Both keep lithium as a first-line maintenance option, which is a stronger position than some other countries take.

Australia's heat matters for lithium. Stems set in summer, in outback work, or after a long day outdoors are hinting at dehydration and toxicity. Patients are advised to drink enough fluid in hot weather and to seek review if they develop vomiting or diarrhoea.

Because mania often impairs insight, Mental Health Act questions may use a manic patient. The criteria are state-based, but in every jurisdiction the reasoning is the same: mental illness, need for treatment, risk of serious harm, including to reputation and finances in some Acts, and no less restrictive option.

For pregnancy, perinatal mental health services and the COPE national perinatal guideline support planning before conception. Lithium may be continued in pregnancy in some women with specialist input and closer level monitoring, because the risk of relapse after stopping can outweigh the small increase in cardiac malformation risk.

  • Heat and gastroenteritis are common lithium toxicity triggers in stems
  • Pre-pregnancy planning with a perinatal psychiatrist
  • High postpartum relapse and psychosis risk in bipolar disorder
  • Mental Health Act criteria are state-based but share principles

How to approach bipolar and lithium stems

Start by asking which of the two question types you are facing. If the lead-in asks for a diagnosis, count the days, check for impairment and psychosis, and look for a substance or medical cause. If it asks for management, decide first whether the patient is safe and whether a drug is causing harm.

In any stem where a patient takes lithium and becomes unwell, assume toxicity until proven otherwise. Scan for the trigger: a new tablet, a hot day, vomiting, poor oral intake, or a recent kidney injury. Then pick the option that stops lithium and measures the level and renal function. Options that treat the symptom, such as an antiemetic or a beta blocker for tremor, are distractors.

Tremor needs care. A fine tremor is a common side effect at therapeutic levels and may be managed by reviewing the dose or timing. A coarse tremor with gastrointestinal upset, ataxia or confusion is a toxicity sign. The adjectives in the stem are deliberate.

For a manic patient who refuses care, look for the option that keeps them safe in the least restrictive way. That is often assessment under the Mental Health Act and admission, with an antipsychotic or mood stabiliser, rather than discharge with outpatient follow-up.

  • Count the days: four for hypomania, seven for mania
  • Psychosis or admission always means mania
  • New drug plus lithium plus confusion: toxicity
  • Fine tremor is a side effect; coarse tremor with ataxia is toxicity
  • Polyuria and thirst on lithium: think nephrogenic diabetes insipidus
Mood stabilisers: what the AMC expects you to know
DrugKey monitoring or riskExam trigger
LithiumLevels, renal, thyroid, calciumNew NSAID, ACE inhibitor, thiazide or dehydration
Lithium (long-term)Hypothyroidism, CKD, nephrogenic DI, hypercalcaemiaPolyuria, weight gain, tiredness
ValproateTeratogenic; liver function; weight gainYoung woman planning pregnancy
LamotrigineSerious rash with fast titrationRash in first weeks; co-prescribed valproate
CarbamazepineHyponatraemia, agranulocytosis, enzyme inductionContraceptive failure; low sodium
QuetiapineSedation, weight gain, metabolic syndromeBipolar depression treatment option
OlanzapineMarked weight gain and metabolic riskAcute mania; check weight, lipids, glucose

Worked examples in AMC style

Pick an answer to see why each option is right or wrong. These examples are written for this page; the bank holds the full set for bipolar disorder & lithium.

Example 1

A 56-year-old man with bipolar I disorder has been stable on lithium for years. His GP started him on hydrochlorothiazide for hypertension three weeks ago. He now has nausea, diarrhoea, a coarse tremor and an unsteady gait. His wife says he seems slow and muddled. He is haemodynamically stable.

What is the most appropriate next step in management?

Show answer and reasoning

Answer: D. Stop lithium and check level and renal function

  • A. These are signs of toxicity, not relapse. More lithium would worsen harm.
  • B. Activated charcoal does not bind lithium.
  • C. Treating nausea misses a potentially dangerous drug toxicity.
  • D. Thiazides reduce lithium excretion. Coarse tremor, ataxia and confusion suggest toxicity, so stop lithium and check level and renal function urgently.
  • E. Loop diuretics also affect lithium handling, and the priority is to stop lithium and assess toxicity.

On lithium with a new thiazide, NSAID or ACE inhibitor plus tremor and confusion: stop lithium and check level and renal function.

Based on: Therapeutic Guidelines: Psychotropic; Therapeutic Guidelines: Toxicology and Toxinology

Example 2

A 26-year-old woman presents with four weeks of low mood, hypersomnia and poor concentration. Eighteen months ago she had a week of very little sleep, rapid speech and excessive spending, and was admitted to hospital with grandiose beliefs. She is not pregnant and uses an intrauterine device. She has no suicidal thoughts.

Which treatment is the most appropriate choice?

Show answer and reasoning

Answer: A. Quetiapine under psychiatric supervision

  • A. She has bipolar I depression. Quetiapine is an evidence-based option for bipolar depression and avoids antidepressant monotherapy.
  • B. Antidepressant monotherapy in bipolar I disorder risks switching to mania.
  • C. Valproate is teratogenic and has weaker evidence for bipolar depression; it is not preferred in a woman of childbearing potential.
  • D. Venlafaxine has a relatively high switch risk and should not be used without a mood stabiliser.
  • E. She has a clear depressive episode in bipolar I disorder that needs pharmacological treatment.

Bipolar depression: avoid antidepressant monotherapy; choose an agent with evidence such as quetiapine or lithium.

Based on: RANZCP clinical practice guidelines for mood disorders

Example 3

A 33-year-old man is brought to ED by police after shouting at shoppers. He has slept two hours a night for ten days, speaks rapidly, says he is a billionaire advising the Prime Minister and has spent his savings. He has no history of drug use and his urine drug screen is negative. He refuses admission.

What is the most likely diagnosis?

Show answer and reasoning

Answer: C. Manic episode with psychotic features

  • A. Hypomania does not include psychotic features or marked impairment.
  • B. Schizophrenia does not usually present with reduced need for sleep, pressured speech and overspending over days.
  • C. Ten days of elevated mood with reduced sleep, pressured speech, overspending and a grandiose delusion is mania with psychotic features.
  • D. There is no history or screen evidence of drug use to support a substance-induced cause.
  • E. Personality disorder is a long-standing pattern, not an acute episode with reduced sleep and psychosis.

Mania with delusions is still mania; psychotic features rule out hypomania.

Based on: DSM-5-TR criteria; RANZCP mood disorders guideline

Quick recall

Tap a card to turn it over. If you can answer all eight without looking, move on to timed questions.

Where candidates lose marks

  • Calling psychotic mania hypomania

    Psychotic features or hospital admission mean mania, regardless of duration.

  • Antidepressant monotherapy

    In bipolar depression an antidepressant alone can trigger mania. Combine with a mood stabiliser if one is used at all.

  • Charcoal for lithium overdose

    It does not bind lithium. Fluids, stopping the drug and dialysis for severe cases are the answer.

  • Valproate in a young woman

    Unless there is no alternative and strict conditions are met, valproate is the wrong choice in women who could become pregnant.

  • Trusting a normal level

    In chronic toxicity a patient can be very unwell with a level that is only mildly raised. Treat the clinical picture.

How to study bipolar disorder & lithium

  1. Step 1: Learn the duration and severity rules for mania, hypomania and the bipolar types.

  2. Step 2: Learn the acute mania sequence: safety, stop antidepressants, exclude causes, start antimanic drug.

  3. Step 3: Make a lithium card: baseline tests, level timing, side effects, interactions, toxicity signs and management.

  4. Step 4: Learn the valproate, lamotrigine and carbamazepine safety points.

  5. Step 5: Review bipolar disorder in pregnancy and the postpartum period.

  6. Step 6: Do a block of bipolar and lithium questions and write a one-line rule for each mistake.

Practise bipolar disorder & lithium free

Bipolar disorder & lithium: questions candidates ask

Do I need to know the exact lithium target range?

Know that target ranges differ for acute and maintenance treatment and that levels are taken about 12 hours after a dose. The exam focuses more on toxicity triggers, signs and management than on a single number.

Is lithium still first-line in Australia?

Yes. Australian guidance keeps lithium as a first-line maintenance treatment for bipolar disorder, and it has the best evidence for reducing suicide among mood stabilisers.

What should I do if a patient on lithium has gastroenteritis?

Dehydration raises lithium levels. Advise the patient to seek review, and consider withholding lithium temporarily and checking a level and renal function, especially if they develop tremor or confusion.

How do I separate bipolar II from recurrent depression in a stem?

Look for a past period of at least four days of increased energy, reduced need for sleep or unusual productivity that others noticed. If present, it is bipolar II, which changes treatment.

Can a manic patient be treated involuntarily?

Yes, if they meet their state Mental Health Act criteria. Mania often impairs insight and judgement, and the risk of harm can include financial and reputational harm as well as physical harm.

Practise bipolar disorder & lithium until the decisions are automatic

Free account, 50 questions, full explanations. Upgrade only if it helps.